Implications of SARSr-CoV 2 infection in thalassemias: Do patients fall into the "high clinical risk" category?


Journal

Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064

Informations de publication

Date de publication:
11 May 2020
Historique:
received: 21 04 2020
accepted: 21 04 2020
entrez: 19 5 2020
pubmed: 19 5 2020
medline: 23 5 2020
Statut: epublish

Résumé

We're all flying blind regarding coronavirus, but it's fair to think if thalassemic patients are particularly vulnerable to SARS-COV-2  infection or are at potential higher risk of complications from COVID-19 than normal population, specially when they become older. The frustrating thing is that, right now,  this virus is still new. It only came to the attention of the World Health Organization at the end of December. Very few cases in thalassemia have so far been reported; is this due to lack of testing or a true lack of infection/susceptibility? However, we believe that more data should be collected to better characterise the impact of SARS-CoV-2 infection in patients with thalassemias. Therefore, a multicenter registry and the collection of comprehensive data from both positive COVID-19 thalassemia major and non-transfusion dependent thalassemia are necessary to clarify debated issues. In the meantime an early and vigilant monitoring along with high quality supportive care are needed in thalassemic patients at high risk for SARS-CoV-2 infection.

Identifiants

pubmed: 32420925
doi: 10.23750/abm.v91i2.9592
pmc: PMC7569622
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

50-56

Références

N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Mediterr J Hematol Infect Dis. 2019 May 01;11(1):e2019029
pubmed: 31205633
Eur J Clin Invest. 2002 Mar;32 Suppl 1:70-8
pubmed: 11886435
Acta Biomed. 2020 May 11;91(2):218-221
pubmed: 32420950
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Acta Haematol. 2008;120(4):225-31
pubmed: 19218790
Endocrine. 2020 Apr;68(1):2-5
pubmed: 32279224
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Hemoglobin. 2019 Mar;43(2):95-100
pubmed: 31179787
Mediterr J Hematol Infect Dis. 2020 Jan 01;12(1):e2020006
pubmed: 31934316
Circ Cardiovasc Imaging. 2015 Aug;8(8):e003230
pubmed: 26253625
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Ann N Y Acad Sci. 2005;1054:118-23
pubmed: 16339657
Cent Eur J Immunol. 2016;41(1):116-24
pubmed: 27095931
Indian J Endocrinol Metab. 2013 Nov;17(6):1046-52
pubmed: 24381882
Mediterr J Hematol Infect Dis. 2016 Jul 01;8(1):e2016034
pubmed: 27413526
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Cytokine. 2006 Sep;35(5-6):253-7
pubmed: 17081768
J Clin Med. 2019 Dec 16;8(12):
pubmed: 31888124
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Orphanet J Rare Dis. 2010 May 21;5:11
pubmed: 20492708
Pediatr Hematol Oncol. 2002 Jan-Feb;19(1):51-8
pubmed: 11787867
Diabetes Care. 2018 Oct;41(10):2127-2135
pubmed: 30104296
Acta Biomed. 2019 Jan 15;89(4):481-489
pubmed: 30657116
Transfus Med Rev. 2020 Apr;34(2):75-80
pubmed: 32107119
Viruses. 2020 Jan 24;12(2):
pubmed: 31991541
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
J Pediatr Hematol Oncol. 2015 Jan;37(1):54-9
pubmed: 24942024
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
J Infect Dis. 2000 Sep;182 Suppl 1:S115-21
pubmed: 10944493
J Pediatr Hematol Oncol. 2016 Jan;38(1):5-11
pubmed: 26583617
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Am J Hematol. 2020 Aug;95(8):E198-E199
pubmed: 32311145
Eur Heart J Cardiovasc Imaging. 2018 Mar 1;19(3):299-309
pubmed: 28200076
JHEP Rep. 2020 Jun;2(3):100113
pubmed: 32289115
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cell Host Microbe. 2020 Mar 11;27(3):325-328
pubmed: 32035028
Ann Clin Lab Sci. 2000 Oct;30(4):354-65
pubmed: 11045759
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Ann Hematol. 2009 Jan;88(1):21-7
pubmed: 18690440
Mol Aspects Med. 1997;18 Suppl:S7-13
pubmed: 9266501
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Cardiovasc Magn Reson. 2011 Apr 26;13:23
pubmed: 21518461
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Br J Haematol. 2006 Oct;135(2):254-63
pubmed: 17010049
Blood Cells Mol Dis. 2017 Jul;66:24-30
pubmed: 28806577

Auteurs

Mehran Karimi (M)

Hematology Research Center, Shiraz University of Medical Sciences Shiraz, Iran. vdesanctis@libero.it.

Vincenzo De Sanctis (V)

Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy. vdesanctis@libero.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH